NeuroOne Medical Technologies Corporation (NMTC)
| Previous Close | 0.8000 |
| Open | 0.8000 |
| Bid | 0.7501 x 100 |
| Ask | 0.8583 x 100 |
| Day's Range | 0.7502 - 0.8305 |
| 52 Week Range | 0.6470 - 2.0000 |
| Volume | |
| Avg. Volume | 132,601 |
| Market Cap | 22.382M |
| Beta (5Y Monthly) | 0.95 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5800 |
| Earnings Date | Aug 12, 2024 - Aug 16, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 3.15 |
GlobeNewswireNeuroOne® Announces First in Human Ablations Completed with OneRF™ Ablation System
Five ablations performed successfully in one patient Procedure performed at patient’s bedside saving time and cost associated with the operating room EDEN PRAIRIE, Minn., June 25, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announced that the OneRF Ablation System was recently used at a
- GlobeNewswire
NeuroOne® Granted Approval of ICD-10 Procedure Code for sEEG RF Ablation
ICD-10-PCS code for first to market, FDA-cleared thin-film, sEEG-guided RF ablation system effective October 1, 2024 Specific procedure code positions OneRF™ Ablation System for broader adoption and awareness throughout the healthcare system EDEN PRAIRIE, Minn., June 20, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from ne
- GlobeNewswire
NeuroOne® Reports Second Quarter Fiscal Year 2024 Financial Results and Provides Corporate Update
EDEN PRAIRIE, Minn., May 14, 2024 (GLOBE NEWSWIRE) -- NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) (“NeuroOne” or the “Company”), a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, today announces its operating results for the second quarter fiscal year 2024 ended March 31, 2024. Second Quarter Fiscal Year 2024 and Recent Business Updates Financial Highlights: Product revenue of $1,377,000 in Q2 202
